Ftse Mib
33.629,21
-0,32%
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
NASDAQ
16.156,33
1,99%
Bitcoin
64.021,38
0,03%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ChemoCentryx Inc (CCXI) ChemoCentryx Inc (CCXI) Notizie

CCXI

ChemoCentryx (CCXI)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CCXI
DataOraFonteTitoloSimboloCompagnia
25/10/202201:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CCXIChemoCentryx Inc
20/10/202215:28Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:CCXIChemoCentryx Inc
20/10/202215:27Edgar (US Regulatory)Post-effective Amendment to an Automatic Shelf Registration of Form S-3asr or Form F-3asr (posasr)NASDAQ:CCXIChemoCentryx Inc
20/10/202215:20Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CCXIChemoCentryx Inc
20/10/202215:05PR Newswire (US)AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYXNASDAQ:CCXIChemoCentryx Inc
20/10/202214:41Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:CCXIChemoCentryx Inc
17/10/202214:30GlobeNewswire Inc.ChemoCentryx Announces Presentations at the 2022 American Society of Nephrology and American College of Rheumatology Annual MeetingsNASDAQ:CCXIChemoCentryx Inc
07/10/202222:36Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:CCXIChemoCentryx Inc
05/10/202214:30GlobeNewswire Inc.ChemoCentryx Announces Upcoming Presentations for Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual MeetingNASDAQ:CCXIChemoCentryx Inc
14/09/202223:32Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:CCXIChemoCentryx Inc
12/09/202217:14Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:CCXIChemoCentryx Inc
31/08/202223:08Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:CCXIChemoCentryx Inc
24/08/202214:30GlobeNewswire Inc.ChemoCentryx Announces TAVNEOS® (avacopan) Presentations at Upcoming Medical ConferencesNASDAQ:CCXIChemoCentryx Inc
09/08/202215:40TipRanksAnalysts Offer Insights on Healthcare Companies: ChemoCentryx (CCXI) and ATI Physical Therapy (ATIP)NASDAQ:CCXIChemoCentryx Inc
09/08/202214:30GlobeNewswire Inc.ChemoCentryx Cancels Second Quarter 2022 Financial Results Conference CallNASDAQ:CCXIChemoCentryx Inc
04/08/202215:12Dow Jones NewsChemoCentryx Shares Soar Premarket on Amgen Takeover DealNASDAQ:CCXIChemoCentryx Inc
04/08/202214:00PR Newswire (US)AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASHNASDAQ:CCXIChemoCentryx Inc
02/08/202222:05GlobeNewswire Inc.ChemoCentryx to Hold Second Quarter 2022 Financial Results Conference Call on Tuesday, August 9, 2022NASDAQ:CCXIChemoCentryx Inc
05/07/202214:30GlobeNewswire Inc.ChemoCentryx Announces Appointment of Jennifer L. Herron to Board as Independent DirectorNASDAQ:CCXIChemoCentryx Inc
06/06/202216:15TipRanksH.C. Wainwright Sticks to Its Buy Rating for ChemoCentryx (CCXI)NASDAQ:CCXIChemoCentryx Inc
06/06/202214:30GlobeNewswire Inc.ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:CCXIChemoCentryx Inc
31/05/202222:05GlobeNewswire Inc.ChemoCentryx Announces Abstracts at June Rheumatology, Oncology and Nephrology ConferencesNASDAQ:CCXIChemoCentryx Inc
31/05/202214:30GlobeNewswire Inc.ChemoCentryx Announces Changes to its Board of DirectorsNASDAQ:CCXIChemoCentryx Inc
22/05/202210:46TipRanksCan ChemoCentryx Control Challenging Capital Complications?NASDAQ:CCXIChemoCentryx Inc
18/05/202214:30GlobeNewswire Inc.ChemoCentryx Announces Presentation at the Society for Investigative Dermatology Meeting Highlighting the Role of Tunnels in Driving Ongoing Disease in Hidradenitis SuppurativaNASDAQ:CCXIChemoCentryx Inc
16/05/202214:30GlobeNewswire Inc.ChemoCentryx to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:CCXIChemoCentryx Inc
11/05/202214:30GlobeNewswire Inc.ChemoCentryx Announces Upcoming Conference Abstracts Focused on TAVNEOS® (avacopan) and the Burden of Systemic Glucocorticoid Use in ANCA-Associated VasculitisNASDAQ:CCXIChemoCentryx Inc
10/05/202222:35Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CCXIChemoCentryx Inc
09/05/202209:26TipRanksRaymond James Maintains Their Buy Rating on ChemoCentryx (CCXI)NASDAQ:CCXIChemoCentryx Inc
09/05/202204:18TipRanksChemoCentryx (CCXI) Receives a Buy from Stifel NicolausNASDAQ:CCXIChemoCentryx Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CCXI

La tua Cronologia

BIT
ISP
Intesa Sanpaolo
BIT
UCG
Unicredit
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
STLAM
Stellantis NV
BIT
ENEL
Enel
BIT
STMMI
ST Microelectronics
BIT
BPE
Bper Banca
BIT
BAMI
Banco BPM
BIT
ENI
Eni
BIT
RACE
Ferrari NV
BIT
TIT
Telecom Italia
BIT
SPM
Saipem
BIT
SRG
Snam
BIT
TEN
Tenaris
BIT
TRN
Terna Trasmissione Elett...
BIT
IVG
Iveco Group NV
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network